Baxter reports financial results

07/22/2010 | Wall Street Journal, The

Baxter International reported a decrease in earnings for the second quarter, owing to economic and product issues. The company expects sales of its plasma protein and antibody therapy products to decline for the rest of the year because of continued market issues. It also said it has stepped up its strategies to strengthen sales of Gammagard, a plasma-based drug.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC